Acute CRPS type 1 with inflammatory signs
Conditions
Interventions
Subjects are assigned to receive either intraveneous Infliximab (5mg/kg) or placebo 3 times in 6 weeks.
Sponsors
Erasmus MC, Department of Anesthesiology, Rotterdam, The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: Men and women between 18 and up until 65 years. Established diagnosis of CRPS-1 according to the Bruehl / Budapest criteria. Are considered eligible according to tuberculosis screening criteria.
Exclusion criteria
Exclusion criteria: 1. Disease related reasons; 2. Abnormal laboratory findings; 3. Adverse co-medication (such as corticosteroids, NSAIDs); 4. In general: concomitant congestiv heart failure, pregnancy, receiving other recombinat products, history of serious infections, HIV, hepatitis B or C, abnormal chest radiograph, history of lymphoproliferative disease, opportunistic infection (e.g. herpes zoster), presence of a transplanted solid organ, history of alcohol abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in clinical signs of regional inflammation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in subjective scores of quality of life. Normalization of levels of inflammatory mediators in fluid of induced blisters. | — |
Contacts
Public ContactF.J. Zijlstra
Erasmus Medical Center, Department of Anesthesiology, P.O. Box 2040
Outcome results
None listed